Emerging Illicit Drug "2C": A Case Report on Its Hallucinogenic and Stimulant Properties.
| Autor: | Nasr M; Psychiatry, St. George's University School of Medicine, True Blue, GRD., Assadi B; Psychiatry, St. George's University School of Medicine, True Blue, GRD., Weissman BC; Medicine, St. George's University School of Medicine, True Blue, GRD., Gleason O; Psychiatry, University of New England, Biddeford, USA., Seikunas J; Psychiatry, Bergen New Bridge Medical Center, Paramus, USA., Puthiyathu M; Psychiatry, Bergen New Bridge Medical Center, Paramus, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2024 Sep 14; Vol. 16 (9), pp. e69407. Date of Electronic Publication: 2024 Sep 14 (Print Publication: 2024). |
| DOI: | 10.7759/cureus.69407 |
| Abstrakt: | "2C," formally known as 4-bromo-2,5-dimethoxyphenethylamine, is an illicit drug that combines elements of ketamine, MDMA (ecstasy), methamphetamine, cocaine, and opioids. This report highlights the emergence of 2C compounds, a new class of illicit drugs recognized for their distinctive blend of hallucinogenic and stimulant properties. We present the case of a 22-year-old female who was admitted to the psychiatric emergency department with a history of bipolar I disorder and recent use of various illicit substances, including the drug known as 2C. The patient exhibited symptoms such as visual hallucinations, euphoria, and an increased heart rate. Laboratory tests and toxicology screens were performed to confirm the presence of the components associated with the 2C compound. Her management involved admission to an acute inpatient psychiatric unit for medication stabilization. This case underscores the critical need for healthcare providers to recognize the signs and symptoms of 2C compound intoxication and to provide timely, appropriate intervention. With the rise in recreational use of such substances, further research and public health initiatives are essential to address the associated risks. Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Nasr et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|